LY
Lyka Labs Ltd (LYKALABS)
₹93.41
Mkt cap
₹341 Cr
P/E ratio
—
P/B
3.52
Div yield
0.00%
ROE
−10.20%
ROCE
−5.98%
EPS (TTM)
—
Book value
₹27
52W range
44–93
Sector
Healthcare
Price history
Previous close
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages [1]
NSE LYKALABSBSE 500259
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
0.00% from high₹93
₹44+111.81% from low₹93
Current
₹93.41
Prev close
₹91.58
Day
+2.00%
Price performance
1D
+2.00%
1W
+10.39%
1M
+13.03%
3M
+29.41%
6M
+52.46%
1Y
+6.23%
YTD
+13.38%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 | 36.66 | 30.73 | 28.03 | 42.31 | 44.20 | |
| YoY Sales growth | +9.64% | +82.72% | +24.87% | +31.60% | +47.05% | +3.81% | +20.38% | +9.70% | -10.93% | -9.08% | -16.15% | +28.10% | +20.57% | |
| Expenses | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 | 39.20 | 29.08 | 34.48 | 37.76 | 40.68 | |
| Operating Profit | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 | -2.54 | 1.65 | -6.45 | 4.55 | 3.52 | |
| OPM % | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% | -6.93% | 5.37% | -23.01% | 10.75% | 7.96% | |
| Other Income | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 | 1.16 | 0.61 | 0.42 | 0.62 | |
| Interest | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.70 | 1.01 | 1.02 | |
| Depreciation | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 | 2.01 | 2.05 | |
| Profit before tax | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 | -4.39 | -0.16 | -8.58 | 1.95 | 1.07 | |
| Tax % | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% | -26.65% | -6.25% | -6.06% | -5.13% | -18.69% | |
| Net Profit | -0.49 | 1.78 | -2.09 | 1.29 | 1.91 | 2.70 | 2.03 | 0.99 | -3.22 | -0.15 | -8.07 | 2.05 | 1.27 | |
| EPS in Rs | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 | -0.94 | 0.00 | -2.13 | 0.57 | 0.36 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202658.45%Promoter
Promoters58.45%
FIIs0.15%0.02
DIIs0.66%
Public40.73%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Lyka Labs | ₹93.41 | — | 341 | 0.00% | 1 | +138.39% | 44 | +20.57% | −5.98% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings3
Announcements5
Revised Intimation Of NSE Notice For Imposition Of Fine 3 Nov - NSE fined Lyka Labs ₹1.62 lakh plus GST for delayed FY2025-26 annual report submission.Intimation Of NSE Notice And Imposition Of Fine 2 Nov - NSE imposed ₹1.62 lakh plus GST fine for delayed FY2025-26 annual report submission.Announcement under Regulation 30 (LODR)-Newspaper Publication 31 OctAnnouncement under Regulation 30 (LODR)-Change in Directorate 30 Oct - Lyka Labs approved Q2 FY2026 results, postal ballot, and Neeraj Golas’ 3-year independent director reappointment.Announcement under Regulation 30 (LODR)-Change in Management 30 Oct - Board approved Q2 FY2026-27 standalone and consolidated results; reappointed Neeraj Golas as independent director from 16 January 2027, subject to shareholder approval.






